ImmunityBio (IBRX) AI Stock Analysis

• Market Cap: $2.10B
• Dividend Yield: N/A
• Average Volume (3M): 8.92M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.29
• Revenue Growth: 1025.95%
• EPS Growth: 52.91%
• Country: US
• Employees: 671
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 984,965,150
• 10 Day Avg. Volume: 9,045,365
• 30 Day Avg. Volume: 8,924,850
• PEG Ratio: 0.09
• Price to Book (P/B): -3.66
• Price to Sales (P/S): 121.07
• P/FCF Ratio: -4.48
• Enterprise Value/Market Cap: 1.40
• Enterprise Value/Revenue: 35.53
• Enterprise Value/Gross Profit: 37.49
• Enterprise Value/Ebitda: -12.61
• 1Y Price Target: $7.00
• Price Target Upside: 196.61% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $2.50 ▲(5.93% Upside)

ImmunityBio's overall stock score is primarily impacted by its financial performance challenges, including negative equity and cash flow issues. Technical analysis shows a mixed trend with no strong momentum, and valuation metrics are weak due to ongoing losses.

Positive Factors

Revenue Growth

The company's strong revenue growth reflects its expanding market presence and successful product adoption, which is crucial for long-term sustainability.

Product Innovation

Focus on innovative immunotherapy positions ImmunityBio as a leader in addressing high unmet medical needs, enhancing its competitive advantage.

Strategic Partnerships

Partnerships provide financial support and market access, enabling ImmunityBio to leverage external expertise and resources for growth.

Negative Factors

Negative Equity

Negative equity indicates financial instability, limiting the company's ability to fund operations and invest in growth opportunities.

Cash Flow Challenges

Persistent cash flow issues can hinder operational flexibility and the ability to invest in R&D, affecting long-term growth prospects.

Profitability Struggles

Ongoing profitability challenges reflect operational inefficiencies, potentially impacting the company's ability to achieve sustainable growth.

ImmunityBio Business Overview & Revenue Model

Company Description

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.

How the Company Makes Money

ImmunityBio generates revenue through a combination of product sales, collaborations, and partnerships. The company is actively engaged in clinical trials to develop its immunotherapy products, which, upon successful commercialization, can lead to significant revenue from sales. Additionally, ImmunityBio enters into strategic collaborations and licensing agreements with larger pharmaceutical companies, which may provide upfront payments, milestone payments based on clinical development progress, and royalties on future product sales. The company may also secure funding through grants and government contracts aimed at supporting innovative therapies, further contributing to its revenue streams.

ImmunityBio Financial Statement Overview

Summary

ImmunityBio is experiencing strong revenue growth but faces significant profitability and financial stability challenges. The negative equity and high leverage are concerning, and cash flow issues persist despite some improvement in free cash flow growth. The company needs to address these challenges to improve its financial health.

Income Statement

ImmunityBio shows significant revenue growth in the TTM period, with a 45.86% increase. However, the company is struggling with profitability, as indicated by negative net profit margins and EBIT margins. The gross profit margin is high, but the net income remains negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is negative due to negative equity, and the return on equity is also negative, reflecting poor financial health and high leverage.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a slight improvement in free cash flow growth. The company has a high free cash flow to net income ratio, but the negative operating cash flow coverage ratio indicates cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	82.56M	14.74M	622.00K	240.00K	934.00K	605.00K
Gross Profit	78.23M	14.74M	622.00K	240.00K	934.00K	605.00K
EBITDA	-232.64M	-264.43M	-478.66M	-351.88M	-320.75M	-204.22M
Net Income	-348.62M	-413.56M	-583.20M	-416.57M	-346.79M	-221.85M
Balance Sheet
Total Assets	0.00	382.93M	504.45M	362.36M	468.91M	221.38M
Cash, Cash Equivalents and Short-Term Investments	153.66M	149.81M	266.46M	107.18M	317.12M	96.06M
Total Debt	0.00	504.17M	726.72M	723.77M	645.66M	275.55M
Total Liabilities	569.82M	871.06M	1.09B	812.18M	712.82M	339.87M
Stockholders Equity	-569.82M	-489.10M	-586.99M	-447.33M	-242.17M	-119.81M
Cash Flow
Free Cash Flow	-324.01M	-398.12M	-397.34M	-415.67M	-307.98M	-173.39M
Operating Cash Flow	-319.70M	-391.24M	-366.76M	-337.51M	-274.42M	-171.72M
Investing Cash Flow	-183.54M	-12.25M	-30.47M	27.30M	-84.89M	-19.81M
Financing Cash Flow	452.28M	281.63M	558.34M	233.61M	505.44M	150.68M

ImmunityBio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.36
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBRX, the sentiment is Positive. The current price of 2.36 is above the 20-day moving average (MA) of 2.13, above the 50-day MA of 2.35, and below the 200-day MA of 2.63, indicating a neutral trend. The MACD of -0.05 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 62.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBRX.

ImmunityBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	80 Outperform	$2.88B	13.66	27.52%	―	25.56%	44.42%
ARQT	60 Neutral	$3.79B	―	-28.17%	―	129.21%	80.35%
IMCR	59 Neutral	$1.99B	―	-7.52%	―	27.51%	38.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IBRX	45 Neutral	$2.10B	―	―	―	1025.95%	52.91%
IMVT	45 Neutral	$4.15B	―	-95.93%	―	―	-27.70%
BEAM	44 Neutral	$2.57B	-5.71	-47.19%	―	-84.07%	-157.71%

ImmunityBio Corporate Events

ImmunityBio’s Anktiva: A Promising Treatment for Long COVID?

Study Overview: ImmunityBio Inc. is conducting a clinical study titled ‘Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID.’ The study aims to assess the safety and effectiveness of Anktiva in treating Long COVID, a condition characterized by persistent symptoms following a COVID-19 infection. This research is significant as it addresses the growing need for effective treatments for Long COVID, which affects a substantial number of individuals post-infection.

ImmunityBio’s Innovative Phase 2 Lymphoma Study: A Potential Game-Changer?

ImmunityBio Inc. is conducting an open-label, Phase 2 study titled ‘Open Label, Phase 2 Study of CD19t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma.’ The study aims to evaluate the efficacy of a combination therapy involving CD19t-haNK and N-803 with Rituximab in treating relapsed or refractory B-cell Non-Hodgkin Lymphoma. This research is significant as it explores novel immunotherapy approaches for challenging lymphoma cases.

ImmunityBio’s Anktiva Study: A Potential Breakthrough for Long COVID Treatment

ImmunityBio Inc. is conducting a study titled ‘Single Arm Study to Evaluate the Safety of Nogapendekin Alfa Inbakicept (NAI) in Participants With Long COVID.’ The study aims to assess the safety and effectiveness of Anktiva in treating Long COVID, characterized by persistent symptoms post-COVID-19 infection. This research is significant as it addresses ongoing health challenges faced by COVID-19 survivors.

ImmunityBio’s Shareholder Settlement Gains Preliminary Approval

On July 29, 2025, the United States District Court for the Southern District of California preliminarily approved a proposed settlement of shareholder derivative actions against ImmunityBio‘s individual defendants. The settlement includes corporate governance reforms and attorneys’ fees covered by insurance, with a final approval hearing set for November 4, 2025. The derivative actions alleged breaches of fiduciary duties and misleading statements by ImmunityBio’s officers regarding manufacturing practices, impacting the company’s stock price and leading to a related securities fraud class action.

The most recent analyst rating on (IBRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.

ImmunityBio Reports Revenue Growth Amidst Continued Investments

ImmunityBio, Inc. is a biotechnology company focused on developing next-generation therapies to enhance the immune system’s ability to fight cancers and infectious diseases. The company operates in the healthcare sector, with a unique approach that integrates immunotherapy and cell therapy platforms.